Navigation Links
PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
Date:2/1/2010

ic attack and save American lives," continued Mr. Wright.

About SparVax™

SparVax™ is a novel second generation recombinant protective (rPA) anthrax vaccine being developed for administration by intramuscular injection. This product candidate employs modern vaccine technology to provide a highly purified and well characterized modern vaccine for intended use by the military and civilian Strategic National Stockpile. Phase I and Phase II clinical trials involving more than 750 healthy human subjects have been completed and showed that SparVax™ appears to be well tolerated and induces an immune response in humans. These studies suggest that three doses of SparVax™, administered several weeks apart, should be sufficient to induce protective immunity. In non-clinical studies SparVax™ has also demonstrated the capability to protect rabbits and non-human primates against a lethal aerosol spore challenge of the anthrax Ames strain. The clinical and non-clinical studies for SparVax™ have been carried out under contracts with the National Institute of Allergy and Infectious Diseases and the National Institutes of Health.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ -- a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
2. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
3. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
4. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
5. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
6. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
7. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
8. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
9. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
10. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
11. PharmAthene Reports First Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... it has granted to German life sciences entrepreneurs ... and commercialization of biotechnology (collectively, the "Optionee"), an ... allogenic tumor vaccine technology (the "Technology"), including AEZS-120, ... which is ready to enter a Phase 1 ...
(Date:7/27/2015)... Tenn. , July 27, 2015  Capella ... care services and one of the largest for-profit ... its parent company and sole stockholder, Capella Holdings, ... Properties Trust, Inc. ("MPT") (NYSE: MPW ) ... The transaction is expected to be finalized during ...
(Date:7/27/2015)... --  Inocucor Technologies Inc ., the agriculture biotech ... has received a notice of allowance from the ... application to protect Inocucor consortia and unique microbial ... on farms and in greenhouses. This ... consortium and its fermentation byproducts, which are the ...
(Date:7/27/2015)... NEW YORK , July 27, 2015 ... organizations and startups share information and develop new technology ... The Sachs Policy Group (SPG), a leader in health ... members will now engage in a collaborative innovation process ... through the latest trends in public policy, health care ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4
... 31 Revotar,Biopharmaceuticals AG., today announced first positive ... pilot study in 14 patients with,stable COPD stage ... of Bimosiamose,twice a day. The study was conducted ... Witt and the Respiratory Institute Wiesbaden, Dr.,Beeh. The ...
... Oct. 31 Amedica Corporation,an orthopedic implants company ... the U.S. Food and Drug Administration,has granted 510(k) ... The Valeo(TM) Cervical Plate system combines features aimed ... The,Valeo(TM) Cervical Plate system is intended for anterior ...
... Md., Oct. 31 Micromet, Inc.,(Nasdaq: MITI ... of,novel, proprietary antibody-based products for cancer, inflammation and,autoimmune ... and,Chief Executive Officer of Micromet, will present at ... Conference in New York, on,Wednesday, November 7, 2007 ...
Cached Biology Technology:Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD 2Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007 2
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... is participating in a large-scale, multi-center clinical trial in ... substance, in high doses, can slow the progression of ... million people in the United States. "At present, ... only mask the symptoms they do not alter ...
... have found the "Rosetta Stone" of supervolcanoes, those giant ... massive explosive eruptions that rank among nature,s most violent ... and possibly trigger climatic and environmental effects at ... discovered in the Italian Alps, Sesia Valley by a ...
... 100 billion (1011) neurons, which altogether form about 100 ... mechanism for the generation of this complex wiring pattern ... Hannes Schmidt and Professor Fritz G. Rathjen at the ... have now discovered a molecule that regulates this vital ...
Cached Biology News:Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease? 2'Rosetta Stone' of supervolcanoes discovered in Italian Alps 2'Rosetta Stone' of supervolcanoes discovered in Italian Alps 3MDC researchers discover molecule responsible for axonal branching 2
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
... This goat anti-rabbit IgG FITC ... antibody' for immunofluorescent staining on tissues ... antibody is generated in rabbits. It ... controls, such as omitting the primary ...
... x 25 mm; approximately 1 mm thick, ... sections, sandblasted frosted writing ... markings will not rub off or wash off ... store at room temperature ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Biology Products: